期刊文献+

局部进展期鼻咽癌同期调强放化疗Ⅰ期临床观察 被引量:4

Phase Ⅰ study of concurrent chemotherapy and intensity modulated radiotherapy (IMRT) in locally advanced nasopharyngeal carcinoma
原文传递
导出
摘要 目的前瞻性研究局部进展期鼻咽癌调强放疗联合同期化疗的不良反应,探讨同期调强放化疗的最佳剂量方法。方法2004年8月至2006年3月,20例Ⅲ-Ⅳa期的鼻咽癌患者在北京大学临床肿瘤学院接受了调强放疗和同期化疗。肿瘤靶体积和临床靶体积的放疗中位剂量分别是70、8和61、5Gy。同期化疗采用顺铂和氟尿嘧啶方案,化疗药物分为4个剂量水平。MRI和CT用于疗效评价。CTC2.0评分标准用于评价近期治疗相关的不良反应。结果中位随访时间是16、5个月。随访期间局部区域控制率是100%。2例出现远地转移。放疗结束时影像学评价疗效,完全缓解:20.0%,部分缓解:75.0%,稳定:5.0%。近期治疗相关不良反应随着化疗药物剂量的增加而加重。结论同期调强放化疗的近期不良反应程度与化疗药物剂量明显相关。选择同期化疗剂量时应将3、4度不良反应分别控制在30%~40%和10%以下。 Objective To determine the early toxicity of treatment in the patients with locally advanced nasopharyngeal carcinoma receiving IMRT with concurrent chemotherapy. Methods From Aug 2004 to March 2006, 20 patients were treated with IMRT and concurrent chemotherapy for nasopharyngeal carcinoma(stage Ⅲ-Ⅳa) in Peking University School of Oncology. The median total dose to the gross tumor volume and the clinical target volume was 70.8 and 61.5 Gy, respectively. The protocol of concomitant chemotherapy used in this study was 3 cycles of cisplatin plus fluorouracil. There were four dose-level groups in the study. Treatment related toxicities were scored according to the common toxicity criteria (NCI-CTC Version 2.0). Results The median follow-up period for all patients was 16.5 months. No evidence of local recurrence for them was observed. Two patients had distant metastasis on the eighth month and the eighteenth month after beginning concurrent radiochemotherapy. Complete response and partial response were observed on MRI or CT scan at the end of treatment in 20 % and 75 % patients, respectively. One patient had no response. In the patients with concurrent chemotherapy, radiation induced side-effect of mucous membrane of mouth was significantly associated with dose level of chemotherapy. Conclusions Toxicities related to the treatment are significantly associated with the dose level of chemotherapy. Toxicities of the combination of IMRT and chemotherapy should be controlled by less than 30% to 40% for Grade 3, and 10% for Grade 4.
出处 《中华放射医学与防护杂志》 CAS CSCD 北大核心 2008年第1期63-65,共3页 Chinese Journal of Radiological Medicine and Protection
关键词 鼻咽癌 调强放疗 同期放化疗 近期不良反应 Nasopharyngeal carcinoma Intensity modulated radiotherapy (IMRT) Concomitant radiochemotherapy Early toxicity
  • 相关文献

参考文献12

  • 1Jian JJ, Cheng SH, Tsai SY, et al. Improvement of local control of T3 and T4 nasopharyngeal carcinoma by hyperfractionated radiotherapy and concomitant chemotherapy. Int J Radiat Oncol Biol Phys, 2002, 53 : 344-352.
  • 2Pignon JP, Bourhis J, Domenge C, et al. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three recta-analyses of updated individual data. MACH- NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet, 2000,355 : 949-955.
  • 3Langendijk JA, Leemans CR, Buter J,et al. The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: a meta-analysis of the published literature. J Clin Oncol, 2004,22(22) :4604-4612.
  • 4Kam MKM, Chau RMC, Suen J, et al. Intensity-modulated radiotherapy in nasopharyngeal carcinoma: dosimetric advantage over conventional plans and feasibility of dose escalation. Int J Radiat Oncol Biol Phys,2003 ,56:145-157.
  • 5Trotti A, Byhardt R, Stztz J, et al. Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys, 2000,47 : 13-47.
  • 6Baujat B, Audry H, Bourhis J, et al. Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data metaanalysis of eight randomized trials and 1753 patients. Int J Radiat Oncol Bial Phys,2006,64:47-56.
  • 7Chua D, Sham J, Au G, et al. Concomitant chemoirradiation for stage Ⅲ -Ⅳ nasopharyngeal carcinoma in Chinese patients : results of a matched cohort analysis. Int J Radiat Oncol Biol Phys, 2002,53: 334-343.
  • 8Trotti A, Bellm LA, Epstein JB, et al. Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother Oncol, 2003,66 : 253-262.
  • 9Abitbol A, Abdel-Vabab M, Lewin A, et al. Phase Ⅱ study of tolerance and efficacy of hyperfractionated radiotherapy and 5- Fluorouracil, cisplatin, and paclitaxel (Taxol) in stage Ⅲ and Ⅳ inoperable and/or unresectable head-and-neck squamous cell carcinoma: A-2 protocol. Int J Radiat Oncol Biol Phys, 2002, 53: 942-947.
  • 10Johnson DJ, Scott C, Marks JE. Assessment of quality of life and oral function of patients participating in a phase Ⅱ study of radioprotection of oral and pharyngeal mucosa by the prostaglandin E1 analog misoprostol ( RTOG 96-07). Int J Radiat Oncol Biol Phys, 2002,54 : 1455-1459.

同被引文献29

  • 1雷新,杨晓霞,王东,胡南,刘岩海.鼻咽癌调强放疗和常规放疗早期反应的对照观察[J].解放军医学杂志,2005,30(11):965-966. 被引量:30
  • 2赵充,卢泰祥,韩非,卢丽霞,黄劭敏,邓小武,林承光,崔念基.139例鼻咽癌调强放疗的临床研究[J].中华放射肿瘤学杂志,2006,15(1):1-6. 被引量:154
  • 3何侠,翟振宇,宋丹,张宜勤,魏青,黄生富,李枫,卞秀华.初治鼻咽癌调强放疗布野及联合化疗的临床研究[J].肿瘤学杂志,2006,12(4):282-287. 被引量:17
  • 4[1]Jian JJ.Cheng SH.Tsai SY,et al.Improvement of local control of T3 and T4 nasopharyngeal carcinoma by hyperfractionated radiotherapy and concomitant chemotherapy.Int J Radial Oncol Biol Phys,2002,53:344-352
  • 5[2]Langendijk JA.Leemans CR,Buter J,et al.The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma:a meta-analysis of the published literature,J Clin Oncol,2004,22(22):4604-4612
  • 6[3]Kam MKM.Chau RMC,Suen J,et al.Intensity-modulated radiotherapy in nasopharyngeal carcinoma:dosimetric advantage over conventional plans and feasibility of dose escalation.Int J Radial Oncol Biol Phys,2003,56:145-157
  • 7[6]BaujatB,A udry H,B ourhisJ,et al.Chemotherapy in locally advanced nasopharyngeal carcinoma:an individual patient data meta analysis of eight randomized trials and 1753 patients.Int J Radial Oncol Biol Phys,2006,64:47-56
  • 8[7]Chua D,Sham J,Au G,et al.Concomitant chemoirradialion for stage Ⅲ~Ⅳnasopharyngeal carcinoma in Chinese patients:results of a matched cohort analysis.Int J Radial Oncol Biol Phys,2002,53:334-343
  • 9[8]Abitbol A,Abdel-Vahab M,Lewin A,et al.Phase Ⅱ study of tolerance and efficacy of hyperfractionated radiotherapy and 5-Fuorouracil,cisplatin,and paclitaxel(Taxol)in stage Ⅲ and Ⅳ inoperable and/or unresectable head-and-neck squamous cell carcinoma:A-2 protocol.Int J Radiat Oncol Biol Phys,2002,53:942-947
  • 10[9]Chan AT,Leung SF,Ngan RK,et al.Overall Survival After Concurrent Cisplatin Radiotherapy Compared With Radiotherapy Alone in Locoregionally Advanced Nasopharyngeal Carcinoma.Journal of the National Cancer Institute,2005,97(7):536-539

引证文献4

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部